163 related articles for article (PubMed ID: 22900064)
1. Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.
Burton ER; Gaffar A; Lee SJ; Adeshuko F; Whitney KD; Chung JY; Hewitt SM; Huang GS; Goldberg GL; Libutti SK; Kwon M
Mol Cancer Res; 2011 Aug; 9(8):1126-38. PubMed ID: 21693594
[TBL] [Abstract][Full Text] [Related]
3. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis.
Kwon M; Lee SJ; Wang Y; Rybak Y; Luna A; Reddy S; Adem A; Beaty BT; Condeelis JS; Libutti SK
Int J Cancer; 2014 Jul; 135(1):48-60. PubMed ID: 24327474
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal protein S11 influences glioma response to TOP2 poisons.
Awah CU; Chen L; Bansal M; Mahajan A; Winter J; Lad M; Warnke L; Gonzalez-Buendia E; Park C; Zhang D; Feldstein E; Yu D; Zannikou M; Balyasnikova IV; Martuscello R; Konerman S; Győrffy B; Burdett KB; Scholtens DM; Stupp R; Ahmed A; Hsu P; Sonabend AM
Oncogene; 2020 Jul; 39(27):5068-5081. PubMed ID: 32528131
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected].
Kwon M; Lee SJ; Reddy S; Rybak Y; Adem A; Libutti SK
PLoS One; 2013; 8(12):e82620. PubMed ID: 24340050
[TBL] [Abstract][Full Text] [Related]
6. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms.
Van Ravenstein SX; Mehta KP; Kavlashvili T; Byl JAW; Zhao R; Osheroff N; Cortez D; Dewar JM
EMBO J; 2022 Jun; 41(12):e110632. PubMed ID: 35578785
[TBL] [Abstract][Full Text] [Related]
8. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.
Tyutyunyk-Massey L; Sun Y; Dao N; Ngo H; Dammalapati M; Vaidyanathan A; Singh M; Haqqani S; Haueis J; Finnegan R; Deng X; Kirberger SE; Bos PD; Bandyopadhyay D; Pomerantz WCK; Pommier Y; Gewirtz DA; Landry JW
Mol Cancer Res; 2021 Aug; 19(8):1338-1349. PubMed ID: 33811160
[TBL] [Abstract][Full Text] [Related]
10. Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Wijdeven RH; Pang B; van der Zanden SY; Qiao X; Blomen V; Hoogstraat M; Lips EH; Janssen L; Wessels L; Brummelkamp TR; Neefjes J
Cancer Res; 2015 Oct; 75(19):4176-87. PubMed ID: 26260527
[TBL] [Abstract][Full Text] [Related]
11. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
12. Filamin A interacting protein 1-like as a therapeutic target in cancer.
Kwon M; Libutti SK
Expert Opin Ther Targets; 2014 Dec; 18(12):1435-47. PubMed ID: 25200207
[TBL] [Abstract][Full Text] [Related]
13. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract][Full Text] [Related]
14. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
[TBL] [Abstract][Full Text] [Related]
15. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
16. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
17. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant aberrant Filip1l DNA methylation detected in a murine model of cutaneous squamous cell carcinoma.
Roth K; Coussement L; Knatko EV; Higgins M; Steyaert S; Proby CM; de Meyer T; Dinkova-Kostova AT
EBioMedicine; 2021 May; 67():103383. PubMed ID: 34000624
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
20. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
